Thomas Herrmann

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

Gunnar Folprecht, Thomas Gruenberger, Wolf O. Bechstein et al. · The Lancet Oncology · 2009 · 953 citations

Hepatology, Gastrointestinal Oncology, Medicine +8

Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients

Niels Halama, Inka Zoernig, Anna Berthel et al. · Cancer Cell · 2016 · 486 citations · Full text

Cancer Immunosurveillance, Anti-ccr5 Therapy, Medicine +10

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

David Malka, Pascale Cervera, Stéphanie Foulon et al. · The Lancet Oncology · 2014 · 409 citations · Full text

Advanced Biliary-tract Cancer, Gastrointestinal Oncology, Medicine +7

Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron

Sven G. Gehrke, Hasan Kulaksiz, Thomas Herrmann et al. · Blood · 2003 · 242 citations · Full text

Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4

Katrin Milger, Thomas Herrmann, Christiane Becker et al. · Journal of Cell Science · 2006 · 226 citations

Long-chain Fatty Acids, Biosynthesis, Engineering +14